Anzeige
Mehr »
Login
Dienstag, 30.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
28 Leser
Artikel bewerten:
(0)

The US Market for Rx to OTC Switches, 2015 Edition - Analysis of the $7.8 Billion Industry

DUBLIN, Feb. 23, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/rn97w3/the_us_market_for) has announced the addition of the "The US Market for Rx to OTC Switches, 7th Edition" report to their offering.

600769

Over the past 38 years the U.S. Rx-to-OTC market has grown into a $7.8 billion market

This has mainly been due to factors such as patent expirations, increasing competitiveness with the pharmaceutical environment, brand re-invention, consumer demand, and cost containment strategies. The U.S. market for Rx-to-OTC Switches encompasses a wide variety of products that have been determined safe and effective as over-the-counter products, once only available by prescription.

The current climate of patient-consumer awareness of health issues is continuing to influence the Rx-to-OTC market. Consumers are more prepared to take responsibility for their own health and are willing to purchase medicines over the counter. An increased focus on cost-savings, coupled with the effects of advertising and promotion, result a higher rate of OTC purchases. Aging baby boomers, many of which are taking greater interest in their health, have created a growing Rx-to-OTC industry in America. It is anticipated that Rx-to-OTC switch products will continue to grow as interest from both consumers and developers continue to expand.

The U.S. Market for Rx-to-OTC Switches focuses on several treatment segments in which Rx-to-OTC switches are available. These include:

  • Allergy, Cough, Cold, and Sinus Products
  • Analgesics, NSAIDs, and Pain Treatments
  • Anti-Infectives
  • Gastrointestinal Drugs
  • Hair Loss Products
  • Hormones
  • Oral Care
  • Overactive Bladder
  • Rectal Ointments
  • Sleep-aids
  • Smoking Cessation
  • Weight Loss

In addition to the areas with switches in place, this report has identified other areas which may be open to Rx-to-OTC switches in the future.

These include:

  • Blood Products
  • BPH Treatments
  • Cholesterol-reducing Drugs
  • Hormone Replacement Therapies
  • Migraine Treatments
  • Opioid Overdose Treatment
  • Osteoporosis Treatments
  • Sexual Dysfunction/ Erectile Dysfunction

Key Topics Covered:

  1. Executive Summary
  2. The Otc Drug Industry
  3. Allergy, Cough, Cold, And Sinus Products
  4. Analgesics And Other Pain Relievers
  5. Anti-Infectives
  6. Gastrointestinal Drugs
  7. Smoking Cessation Products
  8. Other Drug Classifications
  9. Profiles For Major Rx-To-Otc Participants
  10. Company Directory
  11. List Of Exhibits
  12. Executive Summary

Companies Featured:

  • Bayer
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
  • Perrigo Company
  • Pfizer
  • Prestige Brands
  • Procter & Gamble
  • Reckitt Benckiser
  • Sanofi/Chattem
  • TEVA

For more information visit http://www.researchandmarkets.com/research/rn97w3/the_us_market_for

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.